| When it comes to platelet function and platelet
inhibition, each patient is different.
If these patients are all inhibited by 50%, with the tests
you use today, can you tell which is at risk for bleeding
intra- or post-op, or which is at risk for an ischemic event?
Now you can. PlateletMapping adds in the missing piece -
the reference point from which to measure your patient’s
response. Now you can anticipate if your patient is at risk
for bleeding or thrombosis.
Consider the individual response of each of these patients
in surgical and prothrombotic scenarios:
| |
Patient
A |
Patient
B |
Patient
C |
| Surgical
scenario: Standard practice is to interrupt antiplatelet
therapy before surgery to prevent bleeding intra- and
post-operatively. |
At 50%
inhibition, the patient remains prothrombotic.
Interrupting antiplatelet therapy makes him extremely
prothrombotic.
At high risk for an ischemic event. |
With 50%
inhibition this patient reaches a therapeutic level.
Interrupting antiplatelet therapy makes him moderately
prothrombotic.
At risk for an ischemic event. |
This patient
starts at a risk for bleeding with 50% inhibition.
Interrupting antiplatelet therapy achieves a therapeutic
level.
Avoids risk of bleeding, while avoiding risk of an ischemic
event. |
| Post-intervention
and prothrombotic scenario: Standard practice
is to use antiplatelet therapy to manage a patient's hypercoagulability. |
This patient's
normal platelet function is extremely prothrombotic.
He remains prothrombotic
even with 50% inhibition.
At risk of an ischemic
event. |
This patient
is moderately prothrombotic.
With 50% inhibition he reaches a therapeutic level.
Probability of an ischemic event reduced. |
This patient
starts with normal platelet function.
50% inhibition makes him hypcoagulable.
He is at risk for bleeding.
Furthermore, if this
patient was resistant to therapy instead of 50% inhibited,
his resistance may be protective of bleeding, since
his reference point remains in the normal range. |
Your current tests show equal inhibition in these patients
without knowing the differences in clinical expression of
that inhibition - because they don’t give a
reference point.
Return to top
|
